BOARD REGULATION NO. 7
Series of 2006

SUBJECT: INSTITUTIONALIZING THE DANGEROUS DRUGS BOARD INTEGRATED DRUG ABUSE DATA INFORMATION NETWORK (DDB IDADIN)

Pursuant to the powers vested in the Dangerous Drugs Board under Section 81 of R.A. 9165 or the Comprehensive Dangerous Drugs Act of 2002, the Integrated Drug Abuse Data Information Network (IDADIN) is hereby institutionalized and, in connection therewith, the following reportorial requirements are hereby prescribed:

Section 1. Short Title - This Regulation shall be known as the “DDB IDADIN Regulation”.

Section 2. Scope - All public and private hospitals, drug/chemical manufacturers, importers, exporters or distributors, forensic laboratories, drug testing laboratories, public and private drug treatment and rehabilitation facilities, accredited physicians, drug law enforcement and prosecution agencies, and penal facilities shall submit a regular written report to the Dangerous Drugs Board on drug-related treatment and/or confinement, transactions and handling of dangerous drugs, controlled precursors and essential chemicals, drug treatment and rehabilitation, drug analysis, drug testing, drug-related arrests, searches and seizures, status of drug cases, and prison population drug profile.

Section 3. Definition of Terms - The terms used in this Regulation are defined as follows:

a. Controlled precursors and essential chemicals – include those listed in Tables I and II of the 1988 UN Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances and made an integral part of RA 9165, as well as those classified as such by the Dangerous Drugs Board;

b. Dangerous drugs – include those listed in the Schedules annexed to the 1961 Single Convention of Narcotic Drugs, as amended by the 1972 Protocol, and in the Schedules annexed to the 1971 Single Convention on Psychotropic Substances and made an integral part of RA 9165, as well as those classified as such by the Dangerous Drugs Board;

c. DDB IDADIN – refers to the Dangerous Drugs Board Integrated Drug Abuse Data Information Network;

d. DOH-Accredited Physician – a doctor engaged in a non-facility-based treatment and rehabilitation duly authorized by the Department of Health to conduct drug dependency examinations and treatment on persons believed to be using dangerous drugs;
e. **Drug analysis** – refers to the process of drug identification or to the systematic characterization of seized drug and chemical means;

f. **Drug/chemical distributor** – refers to any person authorized to engage in the sale of dangerous drugs and/or controlled precursors and essential chemicals on a wholesale basis;

g. **Drug/chemical exporter** – refers to any person authorized to sell or send dangerous drugs and/or controlled precursors and essential chemicals into the customs territory of another country which requires declaration;

h. **Drug/chemical importer** – refers to any person authorized to physically introduce dangerous drugs and/or controlled precursors and essential chemicals into the customs territory of the country which requires declaration;

i. **Drug/chemical manufacturer** - refers to any person authorized to engage in the production, preparation, compounding or processing of any dangerous drugs and/or controlled precursors and essential chemicals, either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis, and shall include any packaging or repackaging of such substances, design or configuration of its form, or labeling or re-labeling of its container, intended for sale;

j. **Drug-related arrest** – apprehension made for violation of R.A. 9165 and other pertinent drug laws as well as other crimes committed under the influence of dangerous drugs;

k. **Drug testing laboratory** – refers to a facility that is capable of testing a specimen for the presence of dangerous drugs;

l. **Drug treatment and rehabilitation** - refers to the process, including after-care and follow-up treatment, directed towards the physical, emotional/psychological, vocational, social, and spiritual change of a drug dependent to enable him/her to live without dangerous drugs, enjoy the fullest life compatible with his capabilities and potentials, and render him/her to become law abiding and productive member of the community;

m. **Forensic laboratory** - refers to the laboratory being maintained by the Philippine National Police, the National Bureau of Investigation and the Philippine Drug Enforcement Agency;

n. **Penal facilities** – refer to penal facilities managed, operated or supervised by the Bureau of Corrections, Bureau of Jail Management and Penology and Provincial Governments;

o. **Prosecution agencies** – refer to the offices of the Provincial, City and Special Prosecutors of the Department of Justice;

p. **Public and private drug treatment and rehabilitation facilities** - any of the facilities, whether residential or out-patient, which undertake treatment, after-care and follow-up of drug dependents, which include institutions, agencies and the like whose purposes are the development of skills, arts and technical know-how, counseling and/or inculcating civic, social and moral values to drug dependent patients, with the aim of weaning them away from dangerous drugs and keeping them drug-free, adapted to their families and peers, and readjusted into the communities as law abiding, useful and productive citizens; and
q. Public and private hospital – refers to a facility that has admitted, examined, or treated a drug related-case, such as overdose, toxic ingestion, chronic effects of drugs, drug-dependency, drug-induced and drug-related suicide, or death, in an emergency, in-patient and out-patient status.

Section 4. Report Forms - In order to ensure uniformity and clarity of reporting, the following attached Forms, which are made an integral part hereof, shall be used, as appropriate:

a. DDB IDADIN Form 1-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 1) - Data on drug-related treatments and admissions in hospitals and detoxification centers; to be reported quarterly by public and private hospitals and detoxification centers;

b. DDB IDADIN Form 2-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 2) – Summary of approved transactions on dangerous drugs; to be reported semi-annually by the Philippine Drug Enforcement Agency;

c. DDB IDADIN Form 3-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 3) – Summary of approved transactions on controlled precursors and essential chemicals; to be reported semi-annually by the Philippine Drug Enforcement Agency;

d. DDB IDADIN Form 4-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 4) – Summary of approved transactions on dangerous drugs/preparations; to be reported semi-annually by licensed importers, exporters, manufacturers and distributors of dangerous drugs/preparations;

e. DDB IDADIN Form 5-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 5) – Summary of approved transactions on controlled precursors and essential chemicals/mixtures; to be reported semi-annually by licensed importers, exporters, manufacturers and distributors of controlled precursors and essential chemicals/mixtures;

f. DDB IDADIN Form 6-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 6) – Data on drug treatment, rehabilitation and aftercare of drug dependents; to be reported quarterly by public and private drug treatment and rehabilitation facilities and accredited physicians;

g. DDB IDADIN Form 7-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 7) – Data on analysis, profiling and composition of seized drugs, controlled precursors and essential chemicals, with the corresponding laboratory report of qualitative and quantitative analyses thereof, including list of equipment, instruments, apparatus, and paraphernalia; to be reported quarterly by forensic laboratories;

h. DDB IDADIN Form 8-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 8) – Data on the results of drug testing; to be reported quarterly by the Department of Health;

i. DDB IDADIN Form 9-06 (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 9) – Data on arrests, searches and seizures for violations of R.A. 9165; to be reported quarterly by the Philippine Drug Enforcement Agency;
j. **DDB IDADIN Form 10-06** (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 10) – Data on cases filed for violations of R.A. 9165 and other crimes committed under the influence of drugs; to be reported quarterly by the Offices of the Provincial and City Prosecutors, Department of Justice;

k. **DDB IDADIN Form 11-06** (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 11) – Data on convicted cases for violations of RA 9165 and/or other crimes committed under the influence of dangerous drugs; to be reported quarterly by the Bureau of Corrections;

l. **DDB IDADIN Form 12-06** (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 12) – Data on cases for violations of RA 9165 and/or other crimes committed under the influence of dangerous drugs; to be reported quarterly by the Bureau of Jail Management and Penology, including city and municipal jails; and

m. **DDB IDADIN Form 13-06** (Dangerous Drugs Board Integrated Drug Abuse Data Information Network Form 13) – Data on cases for violations of RA 9165 and/or other crimes committed under the influence of dangerous drugs; to be reported quarterly by the provincial jails.

Section 5. **Where and When to Submit Reports** - The reports enumerated in the immediately preceding section shall be submitted to the Executive Director of the Dangerous Drugs Board within fifteen (15) days following the period covered by the report.

Section 6. **Criminal Liability** - Refusal or failure to comply with this Regulation shall be punishable under Section 32 of R.A. 9165 or the Comprehensive Dangerous Drugs Act of 2002.

Section 7. **Effectivity** - This Regulation shall take effect fifteen (15) days after its publication in two (2) newspapers of general circulation and after its registration with the Office of the National Administrative Register (ONAR), UP Law Center, Quezon City.

**APPROVED and ADOPTED** this 6th day of December, in the year of Our Lord, 2006 at Quezon City.

[Signature]

Secretary ANSELMO S. AVENIDO, JR.
Chairman, Dangerous Drugs Board

Attested:

[Signature]

Undersecretary EDGAR C. GALVANTE
Secretary of the Board